NorthWest Biotherapeutics Inc (NWBO)

[beachhyena]

NWBIO's website is clearly backing the presented TLD data and this was also available at their booth over ASCO.
Links to all presentations are provided on their website so they are officially backing up all statements made regarding the presentations.
They are not beholden to Fife until they officially seek a private placement which I suspect will come after publication.
TLD data has been officially presented and supported by NWBO. To continually say that this is not fact is just plain stupid IMO.
We are awaiting the Journal which hopefully arrives shortly.

Below is the press release on their website.

Press Release
05
JUN
2022
Northwest Biotherapeutics Announces Presentations On DCVax®-L Personalized Vaccines, Manufacturing and Scale-Up, and DCVax®-L Clinical Program
BETHESDA, Md., June 5, 2022 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported that yesterday on June 4, 2022, in the Industry Expert Theater during the ASCO 2022 conference, Dr. Marnix Bosch made a presentation discussing the Company’s DCVax-L technology for personalized dendritic cell vaccines, the Sawston, UK facility, the manufacturing technology, the development of automation, and preparations for manufacturing scale-up. In addition, a video presentation about the DCVax®-L clinical program was screened in the Company’s exhibit booth in the ASCO Exhibit Hall.

These presentations are now available online at https://virtualtrials.org/dcvax

The Industry Expert Theater is not an official event of the ASCO Annual Meeting. It is not sponsored, endorsed or accredited by ASCO®, CancerLinq®, or Conquer Cancer® the ASCO Foundation. It is not CME-accredited.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both North America and Europe. The Company has a broad platform technology for DCVax® dendritic cell-based vaccines. The Company’s lead program is a 331-patient Phase III trial of DCVax®-L for newly diagnosed and recurrent Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal form of brain cancer, and is an “orphan disease.” This Phase III trial reached data lock and top line data was recently presented. The Company has also developed DCVax®-Direct for inoperable solid tumor cancers. It has completed a 40-patient Phase I trial and, as resources permit, plans to pursue Phase II trials. The Company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania.